Medivolve to Host Live Webinar to Discuss Corporate Update
2022年4月6日 - 6:00AM
Medivolve, Inc. (“
Medivolve” or the
“
Company”) (NEO: MEDV; OTC: COPRF; FRA:4NC) is
pleased to announce that it will be hosting a Corporate Update
presentation with analysts and investors via live webinar on
Thursday April 7th at 12:00pm EST. Participants can register and
submit questions at the following web addresses below:
Registration link:
https://us06web.zoom.us/webinar/register/WN_fVJrJz_KQCu-iE6zKC7yYw
Questionnaire form:
https://kl6modrawsi.typeform.com/to/rMwUeGed
Specifically, the webinar will feature
Medivolve’s Chief Executive Officer, David Preiner, and Chief
Financial Officer, Peter Michel, to discuss updates on the
Company’s business developments as well as the recent financial
results for the fourth quarter ended December 31, 2021.
Additionally, we will be welcoming questions from participants,
through the registration form. We will endeavour to answer as many
questions as possible.
The Company confirms that subsequent to the
press release dated March 31, 2022, there has been no material fact
or material change of the Company that has not been generally
disclosed.
About Medivolve, Inc.
Medivolve, Inc. (NEO: MEDV; OTC: COPRF; FRA:
4NC) is a healthcare technology company that seeks to reinvent the
US healthcare system by leveraging a bespoke telehealth platform, a
clinical diagnostic network, and a data-driven AI framework to
improve patient care.
The company was born out of the healthcare
crisis; to rethink, relearn and ultimately, reimagine a better way
for the healthcare system to operate. Our network of retail
collection sites play an important role in recovery by giving all
Americans access to fast, accurate, and inexpensive clinical
services when and where they need it. These centers will also play
a pivotal role in diagnostic testing, vaccinations, and other
point-of-care services. We are building disruptive technologies to
make it easier and faster to identify, treat, and prevent medical
issues. In doing so, we are working to give patients a holistic and
empowered view of their personal health.
Our long-term mission is to permanently fix
systemic issues in the nation’s fragmented, overly complex, and
expensive healthcare system. Medivolve’s next phase of growth is
about pivoting the model and putting the pieces together to build a
profitable, SaaS-based health-tech company. We are bringing
data-driven clinical diagnostics, physician recommendations, and
prescription medications directly to people, all powered by a
singular, streamlined technology network. Our team is united by a
powerful, singular purpose: harnessing the transformative power of
technology to create healthier lives.
Underpinned by a bespoke, AI-driven platform,
we’re developing a stealth system that constantly gets smarter,
takes the guesswork out of diagnostics, and flags critical health
issues immediately to deliver an unparalleled level of
personalization for each patient. We are determined to push the
boundaries of what’s possible—not just for our business and our
shareholders, but for physicians and patients, and for the future
of healthcare. We are striving to achieve a continuity of care
never seen before, a game changer for our business and for patients
in the communities we serve.
For investing inquiries, please
contact: David
Preiner, info@medivolve.ca, 702-990-3737.
Cautionary Note Regarding Forward-looking
Information
This press release contains “forward-looking
information” within the meaning of applicable Canadian securities
legislation. Forward-looking information includes, but is not
limited to, statements with respect to financial results,
operational results, projections related to the COVID pandemic, the
deployment of the Company’s AI technology platform and patient
portal, the effectiveness of the Company’s testing programs, and
financial guidance and projections. Generally, forward-looking
information can be identified by the use of forward-looking
terminology such as “plans”, “expects” or “does not expect”, “is
expected”, “budget”, “scheduled”, “estimates”, “forecasts”,
“intends”, “anticipates” or “does not anticipate”, or “believes”,
or variations of such words and phrases or state that certain
actions, events or results “may”, “could”, “would”, “might” or
“will be taken”, "occur” or “be achieved”. Forward-looking
information is subject to known and unknown risks, uncertainties
and other factors that may cause the actual results, level of
activity, performance, or achievements of the Company, as the case
may be, to be materially different from those expressed or implied
by such forward-looking information. Although the Company has
attempted to identify important factors that could cause actual
results to differ materially from those contained in
forward-looking information, there may be other factors that cause
results not to be as anticipated, estimated or intended. There can
be no assurance that such information will prove to be accurate, as
actual results and future events could differ materially from those
anticipated in such statements. Accordingly, readers should not
place undue reliance on forward-looking information. The Company
does not undertake to update any forward-looking information,
except in accordance with applicable securities laws.
NEITHER THE NEO EXCHANGE NOR ITS REGULATION
SERVICES PROVIDER HAS REVIEWED OR ACCEPTS RESPONSIBILITY FOR THE
ADEQUACY OR ACCURACY OF THIS RELEASE.
Medivolve (NEO:MEDV)
過去 株価チャート
から 12 2024 まで 1 2025
Medivolve (NEO:MEDV)
過去 株価チャート
から 1 2024 まで 1 2025